Tracking Aggregation of Virus-Like Particles Using Dynamic Light Scattering
JoVE Encyclopedia of Experiments
Microbiologie
0 weergaven • 2:14 min • July 31st, 2026
Loading...
Overview
This article presents an in vitro protocol for assessing the structural integrity of viral capsids by monitoring heat-induced aggregation of virus-like particles (VLPs) using dynamic light scattering (DLS). The method enables real-time tracking of particle aggregation as a result of protein denaturation, providing insights into capsid stability under thermal stress.
Key Study Components
Area of Science
- Virology
- Biophysics
- Protein Chemistry
Background
- Viral capsids are protein shells that protect viral genetic material.
- Virus-like particles (VLPs) mimic the structure of viruses but lack genetic material, making them non-infectious.
- Capsid stability is crucial for vaccine development and viral vector applications.
- Dynamic light scattering (DLS) is a technique used to measure particle size and aggregation in solution.
Purpose of Study
- To provide an alternative in vitro method for determining viral capsid structural integrity.
- To monitor heat-induced aggregation of VLPs as a proxy for capsid stability.
- To demonstrate the use of DLS for real-time tracking of particle aggregation.
Methods Used
- Preparation of a purified, monodisperse suspension of VLPs in buffer.
- Loading the sample into a preheated DLS instrument and allowing temperature equilibration.
- Measurement of particle size changes over time as the sample is heated.
- Analysis of light scattering fluctuations to detect aggregation events.
Main Results
- Heating causes capsid proteins to denature, exposing hydrophobic regions and promoting aggregation.
- DLS detects increases in particle size corresponding to aggregation events.
- Real-time data collection allows for precise tracking of aggregation kinetics.
- The protocol provides reproducible time points for aggregation onset and progression.
Conclusions
- DLS is an effective tool for monitoring viral capsid structural integrity in vitro.
- The method enables rapid, real-time assessment of capsid stability under thermal stress.
- This approach can be applied to quality control and formulation studies for VLP-based products.
Frequently Asked Questions
What are virus-like particles (VLPs)?
VLPs are non-infectious particles that mimic the structure of viruses but lack genetic material, making them safe for laboratory studies.
Why is dynamic light scattering (DLS) used in this protocol?
DLS is used to measure changes in particle size and aggregation in real time, providing insights into capsid stability during heat-induced denaturation.
How does heat affect viral capsid proteins?
Heat causes capsid proteins to denature, exposing hydrophobic regions that lead to particle aggregation detectable by DLS.
What is the significance of monitoring aggregation in VLPs?
Monitoring aggregation helps assess the structural integrity and stability of viral capsids, which is important for vaccine and therapeutic development.
How are time points for aggregation determined in this protocol?
Time points are recorded based on the measurement times in the DLS software, starting from the initial run after temperature equilibration.
Can this method be used for other types of protein particles?
Yes, the DLS-based approach can be adapted to study aggregation and stability of various protein-based nanoparticles.
Executive Industry Relevance
Dynamic light scattering (DLS) enables real-time, quantitative assessment of virus-like particle (VLP) aggregation, directly informing capsid stability and formulation robustness in early biopharma R&D. This approach supports predictive confidence in the structural integrity of VLP-based therapeutics and vaccines, reducing risk at critical discovery and preclinical inflection points. Integrating DLS-based aggregation tracking enhances portfolio decision-making by providing actionable data on candidate stability under stress conditions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of VLP capsid stability under defined thermal stress.
- Supports mechanistic de-risking by quantifying aggregation kinetics linked to protein denaturation.
- Provides functional validation of capsid integrity, informing target selection and triage.
Screening & Assay Development
- Facilitates preparation and validation of monodisperse VLP suspensions for downstream workflows.
- Delivers reproducible, quantitative aggregation measurements for assay standardization.
- Enables screening of formulation conditions to optimize VLP stability profiles.
Translational & Preclinical Research
- Aligns aggregation data with disease-relevant stability requirements for VLP-based therapeutics.
- Supports continuity from discovery through preclinical formulation and stress testing.
- Provides risk-adjusted data for advancing candidates with robust structural profiles.
Pipeline & Workflow Integration
DLS-based aggregation tracking fits within the discovery-to-preclinical continuum, bridging early capsid validation and formulation optimization for VLP-based products.
- Discovery Biology: Quantifies capsid integrity and aggregation onset, supporting hypothesis testing and biological de-risking.
- Screening: Provides standardized, quantitative readouts for formulation and stability screening.
- Analytics: Enables real-time measurement of particle size changes, supporting comparative analysis across conditions.
- Translational Research: Informs preclinical candidate selection based on aggregation resistance under stress.
- Enterprise Reuse: Establishes a reusable platform for VLP and nanoparticle stability assessment across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in VLP stability and reduces mechanistic ambiguity.
- Operational Value: Standardizes aggregation measurement and supports reproducible, scalable workflows.
- Strategic Value: Improves go/no-go decisions and reduces late-stage risk by providing early stability data.
- Portfolio Impact: Enables risk-adjusted prioritization of VLP candidates based on quantitative aggregation profiles.
Implementation Considerations
- Requires expertise in DLS instrumentation and data interpretation.
- Needs access to temperature-controlled DLS systems and validated sample handling protocols.
- Demands cross-team standardization of aggregation measurement procedures.
- May require adaptation for different VLP types or buffer systems.
- Limited to aggregation events detectable by DLS sensitivity and sample clarity.
Biopharma FAQs
Why does null hypothesis testing matter for DLS-based VLP aggregation?
Null hypothesis testing in DLS aggregation studies enables objective assessment of whether observed particle size changes are statistically significant, supporting robust target validation and reducing false positives in capsid stability claims.
How does independent variable isolation fit in heat-induced aggregation tracking?
Isolating temperature as the independent variable allows teams to directly attribute aggregation kinetics to thermal stress, clarifying mechanistic drivers and supporting reproducible discovery-stage experiments.
What do quantitative DLS measurements of particle size enable?
Quantitative DLS outputs provide real-time, reproducible data on aggregation onset and progression, enabling comparative analysis of VLP stability across formulations and conditions.
Why are replication requirements critical for cross-functional DLS studies?
Replication ensures that aggregation measurements are robust and reproducible, facilitating reliable data sharing and decision-making across discovery, formulation, and analytical teams.
Which statistical analysis capabilities are required before DLS implementation?
Teams must be able to analyze DLS-derived size distributions, assess aggregation thresholds, and apply statistical tests to validate observed changes before integrating DLS data into R&D workflows.
09:18
Oereenstemming lichte elektronenmicroscopie (CLEM) voor het bijhouden en Imaging virale eiwitten verbonden structuren in Cryo-geïmmobiliseerd cellen
Gerelateerde video's
0 Bekeken
05:15
Detectie van neutralisatiegevoelige epitopen in antigenen die worden weergegeven op op virusachtige deeltjes (VLP) gebaseerde vaccins met behulp van een capture-assay
Gerelateerde video's
0 Bekeken
08:31
Geavanceerde beeldvorming met hoge resolutie van virusassemblages in vloeistof en ijs
Gerelateerde video's
0 Bekeken
09:16
Meting van de deeltjesgrootteverdeling in Troebele Solutions van Dynamic Light Scattering Microscopy
Gerelateerde video's
0 Bekeken
06:28
Flow Virometry Analyseer antigene Spectra van Virions en extracellulaire blaasjes
Gerelateerde video's
0 Bekeken
07:38
Open-source Single-deeltje Analyse voor Super-resolutie microscopie met VirusMapper
Gerelateerde video's
0 Bekeken
12:57
Alternatieve In Vitro methoden voor de bepaling van de structurele integriteit van virale Eiwitmantel
Gerelateerde video's
0 Bekeken
09:16
Snelle fluorescentie gebaseerde karakterisering van één extracellulaire blaasjes in menselijk bloed met Nanoparticle-tracking analyse
Gerelateerde video's
0 Bekeken
12:15
Beeldverwerking Protocol voor de analyse van de verspreiding en de clustergrootte van membraan receptoren door fluorescentie microscopie
Gerelateerde video's
0 Bekeken
07:51
Toepassing van spanning in dynamic light scattering particle size analysis
Gerelateerde video's
0 Bekeken
Laatst bijgewerkt: 1 augustus 2026